ERGO.L

Ergomed Plc
Ergomed plc - Cancellation of admission to trading of shares
14th November 2023, 07:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2856T
Ergomed plc
14 November 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

 

For immediate release

 

14 November 2023

 

Ergomed plc

 

 

Cancellation of admission to trading of Ergomed Shares

 

 

Further to the announcement on 13 November 2023 that the Scheme for the acquisition of the entire issued and to be issued ordinary share capital of Ergomed plc ("Ergomed" or the "Company") by Eden AcquisitionCo Limited has now become Effective in accordance with its terms, Ergomed confirms that AIM has cancelled the admission to trading of Ergomed Shares on AIM with effect from 7.00 a.m. today, 14 November 2023.

Defined terms used but not defined in this announcement have the meanings set out in the Scheme Document dated 22 September 2023.  All references to times in this announcement are to London time.

Enquiries:

Ergomed                                                                                                           +44 (0) 1483 307 920

Miroslav Reljanović (Executive Chairman)                                              

Jonathan Curtain (Chief Financial Officer)

Keith Byrne (Senior Vice President, Capital Markets and Strategy)          

                                             

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDZMMMVFZGFZM]]>
TwitterFacebookLinkedIn